As of May 27
| +0.07 / +4.96%|
The 2 analysts offering 12-month price forecasts for Galectin Therapeutics Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 6.00. The median estimate represents a +372.97% increase from the last price of 1.48.
The current consensus among 1 polled investment analysts is to Buy stock in Galectin Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.